CCRinCD: Surgical Management of Colorectal Cancer in Crohn's Disease
Trial Overview
| Acronym | CCRinCD |
|---|---|
| Number | NCT04654494 |
| Protocol Link | https://www.clinicaltrials.gov/ct2/show/NCT04654494?term=sica+sensi&draw=2&rank=3 |
| Status | Open/recruiting |
| Category | Colorectal Cancer - All |
| Treatment Course | Surgery |
Trial Description
| Retrospective multicentre study. All patients with a diagnosis of Crohn's disease (CD) and operated for colorectal cancer (CRC) between 01/01/2010 and 01/01/2020 will be included in the dataset. Data will include preoperative, intraoperative and postoperative variables, with long term follow up when feasible. The study will focus on a comparison between patients treated with total proctocolectomy (TPC) and patients treated with subtotal colectomy (STC) or segmental resection (SR). Prima |
Chief Investigator
|
Giuseppe Sica MD, PhD, Associate Professor of Surgery |
| Profile Link |
Lead Centre
|
Policlinico Tor Vergata viale Oxford, 81 Roma 00133 Italia |
| Website |
Additional Information
Full Research Summary| Objective: | Optimal management of colorectal cancer arising in Crohn's disease is uncertain. Current guidelines recommend pan-proctocolectomy (PPC) as a treatment, although evidence is scarce. |
| Aim: | Aim of this study was to evaluate oncologic outcomes and the actual risk of developing metachronous cancers in CD patients undergoing segmental colectomy (SC) vs extended colectomy for CRC. |
| Methods: | All CRC CD patients undergoing surgery between Jan 2010 and Dec 2020 will be retrospectively enrolled. Short and long-term results of SC will be compared with those of patients undergoing extended colectomies: total colectomy (TC) and panproctocolectomy (PPC). Primary outcomes: progression-free survival (PFS) and overall survival (OS). Secondary outcomes: postoperative complications, major complications, 30 days mortality, re-admission, length of stay, incidence of synchronous and metachronous lesions. |
| Reason for International Trial: | Colorectal cancer in Crohn's disease is a relatively rare occurrence and large numbers are welcome to provide best possible evidence. |